Diamonds and Dogs

3/14/25

Tech having a nice bounce. Docusign (DOCU) is jumping 15% following better than expected earnings as sales rose 9% to $776 million. The software firm actually provided downside guidance in the short term, but management is optististic that long term, a newly launched Docusign, AI-powered agreement management platform will drive sales going forward. Citi analysts increased their price target on Docusign to $115 from $113 and reiterated a Buy rating.

Not many stocks are lower. Abbott Laboratories (ABT) is down 2% as a judge ordered a new trial after rejecting a verdict that had cleared the companies of liability over claims, they hid potential risks of their premature-infant formulas.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.